论文部分内容阅读
目的:探讨厄贝沙坦联合胺碘酮治疗老年人心房纤颤患者窦性心律维持的临床效果。方法:将92例患者随机分为治疗组46例和对照组46例,除行病因治疗和营养心肌扩冠等治疗外,治疗组给予厄贝沙坦和胺碘酮治疗,对照组给予胺碘酮治疗。随访12个月,观察两组患者心房颤动的复发率和左房内径的比较。结果:治疗组心房颤动复发5例(10.86%),对照组复发17例(36.95%),两组比较差异有显著性(P<0.05)。治疗12个月后,对照组和治疗组左房内径分别为(39.59±1.25)mm和(36.93±1.41)mm,两组比较差异有显著性意义。结论:厄贝沙坦联合胺碘酮能维持老年人心房纤颤患者的窦性心律,降低心房颤动的复发率,改善左室重构,有效预防心房颤动复发。
Objective: To investigate the clinical effect of irbesartan combined with amiodarone on sinus rhythm maintenance in elderly patients with atrial fibrillation. Methods: Ninety-two patients were randomly divided into treatment group (n = 46) and control group (n = 46). Irbesartan and amiodarone were given to the treatment group and amine iodine Ketone treatment. The patients were followed up for 12 months. The recurrence rate of atrial fibrillation and the left atrial diameter were compared between the two groups. Results: The recurrence rate of atrial fibrillation in the treatment group was 5 cases (10.86%), while that in the control group was 17 cases (36.95%). There was significant difference between the two groups (P <0.05). After 12 months of treatment, the left atrial diameters of the control group and the treatment group were (39.59 ± 1.25) mm and (36.93 ± 1.41) mm, respectively, with significant differences between the two groups. Conclusion: Irbesartan combined with amiodarone can maintain the sinus rhythm of elderly patients with atrial fibrillation, reduce the recurrence rate of atrial fibrillation, improve left ventricular remodeling, and effectively prevent the recurrence of atrial fibrillation.